Evidence map›Paper›PMID 42560422›Full record

ArticleBreast cancer research and treatment2026

Locoregional recurrence and mortality after breast cancer surgery in patients aged 85 and older.

David Foulad, Jacqueline Tsai, Ingrid Luo, Adele Xu, Mina Satoyoshi, Su-Ying Liang, Pragati Kenkare, Summer Han, Allison W Kurian, Irene L Wapnir

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

David FouladDepartment of Surgery, Stanford University School of Medicine, Stanford, CA, USA.
Jacqueline TsaiDepartment of Surgery, Stanford University School of Medicine, Stanford, CA, USA.
Ingrid LuoQuantitative Sciences Unit, Stanford University School of Medicine, Stanford, CA, USA.
Adele XuDepartment of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Mina SatoyoshiDepartment of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Su-Ying LiangPalo Alto Medical Foundation Research Institute and Sutter Health's Center for Health Systems Research, Palo Alto, CA, USA.
Pragati KenkarePalo Alto Medical Foundation Research Institute and Sutter Health's Center for Health Systems Research, Palo Alto, CA, USA.
Summer HanQuantitative Sciences Unit, Stanford University School of Medicine, Stanford, CA, USA.
Allison W KurianStanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Irene L WapnirDepartment of Surgery, Stanford University School of Medicine, Stanford, CA, USA. wapnir@stanford.edu.

Funding

Regents of the University of California's California Breast Cancer Research Program (16OB-0149 and 19IB-0124
6 · The paper itself

Abstract

purposeLife expectancy is increasing and the number of patients age ≥ 85 with breast cancer (BC) may be on the rise. We report descriptive statistics regarding surgical management and outcomes in this cohort.

methodsPatients ≥ 85 years surgically treated for a primary or in-breast tumor recurrence (IBTR) were identified through Oncoshare, a database that links Stanford Healthcare and Sutter Health electronic medical records with the California Cancer Registry.

resultsFrom 2010 to 2019, 91 patients, 65 (71%) aged 85-89 and 26 (29%) ≥ 90 + years were identified. 29.2% were screen-detected compared to 57.7% with a prior BC. Lumpectomy was performed in 70% of 96 cancers, nodal staging in 36% of lumpectomies and 91% of mastectomies. Locoregional recurrences (LRR) occurred in 18 patients, 17 after lumpectomy and two BC-related deaths. BC-specific survival was 100.0% at 3 years and 98.0% (95%CI: 94.3%-100.0%) at 5 years. Overall survival (OS) was 77.9% (95% CI: 68.8%-88.1%) at 3 years and 59.9% (95% CI: 49.3%-72.6%) at 5 years. Five-year OS was 71.9% (95% CI: 60.4%-85.6%) for those 85-89 years vs. 28.3% (95% CI: 13.6%-58.6%) for those ≥ 90 years, (p < 0.001). Life expectancy, estimated as median OS, was 7.6 (85-89)and 3.5 (> 90) years. The cumulative incidence of LRR was 4.6%(95% CI: 2.2-9.0%) at 3 years and 13.4%(95% CI: 5.9-20.8%) at 5 years, factoring death as a competing risk using the Aalen-Johansen estimator.

conclusionSurgery achieves satisfactory local control of disease in patients ≥ 85 years with a new BC or IBTR.

Indexed as

Breast NeoplasmsMastectomyNeoplasm Recurrence, LocalAged, 80 and overFemaleHumansMastectomy, SegmentalNeoplasm StagingBreast cancerElderlyLumpectomyMastectomy

Identifiers

PMID42560422

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.